Shattuck Labs to Present at CD47|Sirpα Summit 2020

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its upcoming presentation at the virtual CD47|SIRPα Summit 2020 on November 5, 2020. The presentation, titled "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity," will be delivered by CEO Taylor Schreiber at 10:45 a.m. EST. Shattuck is developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program SL-172154 currently in a Phase 1 trial.

DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47|SIRPα Summit 2020 being held virtually November 4-5, 2020.

Presentation Details
Presentation Title: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity
Presentation Subtitle: Preclinical and Clinical Development of SL-172154
Date/Time: November 5 at 10:45 a.m. EST
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Location: https://www.cd47sirpa.com/

The presentation will be available for download on the Events & Presentations section of the Company’s website and also will be available to registered participants of CD47|SIRPα Summit 2020.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint platform, ARC®, simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com

FAQ

What is the date of Shattuck Labs' presentation at the CD47|SIRPα Summit 2020?

Shattuck Labs' presentation at the CD47|SIRPα Summit 2020 is scheduled for November 5, 2020.

Who will present for Shattuck Labs at the CD47|SIRPα Summit 2020?

Taylor Schreiber, M.D., Ph.D., the CEO of Shattuck Labs, will present at the summit.

What is the focus of Shattuck Labs' presentation at the summit?

The presentation will focus on the role of CD40 in enhancing type I interferon responses in the context of CD47 blockade.

What is Shattuck Labs' lead program being discussed at the summit?

The lead program discussed is SL-172154, which is currently in a Phase 1 trial.

Where can I find more information about Shattuck Labs' presentation?

More information about the presentation can be found on the Events & Presentations section of Shattuck Labs' website.